| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
GB:0QIU
Novo Nordisk
|
Aug 07, 2026 | HOLD |
Hold
+33.5% avg upside
29 analysts
|
— | · | · |
|
PFE
Pfizer
|
Aug 06, 2026 | BUY |
Buy
+25.8% avg upside
45 analysts
|
— | +3.2% | · |
|
FR:SAN
Sanofi
|
Jul 31, 2026 | BUY |
Strong Buy
+30.0% avg upside
30 analysts
|
— | -0.3% | · |
|
GB:GSK
GlaxoSmithKline
|
Jul 29, 2026 | HOLD |
Hold
+2.1% avg upside
25 analysts
|
— | -0.2% | · |
|
GB:AZN
AstraZeneca
|
Jul 28, 2026 | BUY |
Strong Buy
+23.4% avg upside
26 analysts
|
— | -9.8% | · |
|
GB:0QW0
arGEN X
|
Jul 24, 2026 | BUY |
Strong Buy
-19.2% avg upside
24 analysts
|
— | · | · |
|
CH:NOVN
Novartis AG
|
Jul 22, 2026 | HOLD |
Buy
-11.3% avg upside
32 analysts
|
— | -1.9% | · |
|
CH:ROP
Roche Holding AG
|
Feb 02, 2026 | BUY |
Buy
-8.6% avg upside
23 analysts
|
— | +6.6% | · |
|
ABBV
AbbVie
|
Nov 04, 2025 | HOLD |
Strong Buy
-4.3% avg upside
46 analysts
|
$237.00
3.59% Downside
|
+17.9% | · |
|
NL:PHIA
Koninklijke Philips N.V.
|
Jul 29, 2025 | HOLD |
Buy
+29.4% avg upside
21 analysts
|
— | +1.0% | · |
|
GILD
Gilead Sciences
|
Feb 13, 2025 | BUY |
Strong Buy
-12.1% avg upside
66 analysts
|
$108.00
18.95% Downside
|
+50.3% | · |
|
AMGN
Amgen
|
May 07, 2024 | BUY |
Buy
-23.9% avg upside
57 analysts
|
$343.00
16.50% Downside
|
-5.3% | · |
|
REGN
Regeneron
|
May 06, 2024 | BUY |
Strong Buy
-2.1% avg upside
58 analysts
|
$1065.00
35.85% Upside
|
-41.7% | · |
|
LLY
Eli Lilly & Co
|
May 03, 2024 | HOLD |
Strong Buy
-13.8% avg upside
48 analysts
|
$800.00
32.54% Downside
|
+12.8% | · |
|
BMY
Bristol-Myers Squibb
|
Apr 30, 2024 | BUY |
Buy
-4.4% avg upside
42 analysts
|
$50.00
22.79% Downside
|
+19.9% | · |
|
MRK
Merck & Company
|
Apr 29, 2024 | BUY |
Strong Buy
-0.7% avg upside
43 analysts
|
$148.00
15.04% Upside
|
-33.0% | · |
|
JNJ
Johnson & Johnson
|
Apr 18, 2024 | BUY |
Strong Buy
-9.2% avg upside
39 analysts
|
$176.00
32.06% Downside
|
+11.5% | · |
|
BIIB
Biogen
|
Feb 15, 2024 | HOLD |
Strong Buy
+23.5% avg upside
52 analysts
|
$236.00
13.59% Upside
|
-38.5% | · |
|
PFS
Provident Financial Services
|
Nov 02, 2023 | BUY |
Strong Buy
+29.0% avg upside
16 analysts
|
$39.00
59.46% Upside
|
+32.7% | · |
|
DE:SHL
Siemens Healthineers AG
|
Apr 20, 2022 | HOLD |
Buy
+25.1% avg upside
24 analysts
|
— | -0.7% | · |
|
GSK
GlaxoSmithKline
|
Feb 11, 2022 | HOLD |
Hold
-14.5% avg upside
19 analysts
|
— | -15.5% | · |
|
DE:FPE3
Fuchs Petrolub
|
Aug 24, 2021 | BUY |
Strong Buy
+15.5% avg upside
12 analysts
|
— | -31.2% | · |
|
MDT
Medtronic
|
May 14, 2020 | HOLD |
Buy
+6.9% avg upside
38 analysts
|
$92.00
5.63% Upside
|
+36.5% | · |
|
PHG
Koninklijke Philips
|
Mar 24, 2020 | BUY |
Buy
+34.6% avg upside
13 analysts
|
$41.90
56.65% Upside
|
+57.4% | · |
|
NVO
Novo Nordisk
|
May 03, 2018 | SELL |
Buy
+145.4% avg upside
26 analysts
|
— | -1.2% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.